A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
Market Scope
Trusted Global Partner of Industry and Medical Professionals for Ophthalmic Market Research, Primary Research, Independent Perspective, & Objective Analysis
Choose Your Experience
Over 500 Clients, Large & Small from Around the World, Trust Market Scope Data & Analysis
Latest Market Reports
Market Scope's industry reports are meticulously prepared by a dedicated team of in-house consultants/analysts with over 100 years of collective experience.
- 269
Comprehensive Pages
- 8
Geographic and Economic Breakouts
- 5
Year Market Forecasts
- 52
Diseases Analyzed
2025 Cornea Products Market Report: Global Analysis for 2024 to 2030, December, 2025
The “2025 Cornea Products Market Report” delivers an in-depth analysis of the global cornea market, highlighting the latest advances in transplantation, crosslinking, and therapeutic devices aimed at restoring and preserving vision. The report estimates disease prevalence across six major corneal conditions and examines evolving treatment approaches, including cornea transplants, therapeutic lenses, phototherapeutic keratectomy (PTK), intrastromal ring segments, and corneal crosslinking.
It also explores the global ecosystem that supports cornea care—spanning organ donation systems, regulatory environments, and the pivotal roles of cornea specialists, eye banks, and nonprofit organizations.
This 2025 edition evaluates more than 70 products from over 50 companies, with forecasts for unit demand and revenue growth through 2030. It features analysis of emerging pipeline technologies yet to generate revenue and profiles 12 leading market participants shaping the future of cornea treatment.
Latest Industry News & Trends
10/9/2026
BreakingDealsRetina
Glaukos Licenses Tri-specific Retinal Candidate RO-104 from RevOpsis
Glaukos announced Oct. 8 that it had licensed from RevOpsis Therapeutics the exclusive rights to develop and commercialize RO-104, a novel tri-specific biologic candidate targeting wet age-related ...
10/9/2026
BreakingCataractDealsDiagnosticGlaucomaIOLPerimetryPremium
Carrot, Maker of VR Visual Field Testing, Acquires IOL Simulation Developer GreenMan
Carrot (formerly Virtual Field) reported Oct. 9 that it had agreed to acquire GreenMan Vision, of West Fargo, North Dakota, and its InSightVR IOL simulator. No financial details were provided. The ...
10/9/2026
BreakingDiagnosticRetina
Sagent Launches Zyogreen Ready-to-Use Indocyanine Green Dye for Injection in the US
Sagent Pharmaceuticals, of Schaumburg, Illinois, announced Sept. 22 the US launch of Zyogreen (indocyanine green injection). Sagent said Zyogreen is the first and only FDA-approved ready-to-use ind...
10/9/2026
BreakingGlaucomaStudy
Study Indicates that Circadian Rhythm and Light May Affect IOP
Researchers at the University of South Florida (USF) reported Sept. 30 that continuously monitoring intraocular pressure (IOP) in a rat model showed that eye pressure follows a daily rhythm, consis...
10/9/2026
BreakingGene TherapyRetina
Nobel Prize for Medicine Goes to Team First to Publish Optogenetics Findings
Three scientists who helped develop optogenetics received the 2026 Nobel Prize in Physiology or Medicine on Oct. 5. They are Karl Deisseroth, MD, PhD, of the Howard Hughes Medical Institute in Mary...
10/9/2026
BreakingDealsDiagnostic
VEO Ophthalmics to Market the VitaPixel Visualization System for Slit Lamps
VEO Ophthalmics and VitaPixel announced a collaboration Oct. 2 under which VEO will market the VitaPixel SVS, a stereoscopic digital visualization system for slit lamps. The VitaPixel SVS combines ...
10/9/2026
BreakingGene TherapyRegulationRetina
Japanese Regulators Accept NDA for Nanoscope’s Optogenetic Gene Therapy Candidate, Grant Priority Review
Nanoscope Therapeutics announced Oct. 1 that regulators in Japan had accepted the company’s new drug application for Mogenry, an optogenetic gene therapy candidate targeting inherited retinal dystr...
10/9/2026
BreakingClinical TrialPharmaRegulationRetina
US FDA Gives Green Light to Trial of Surrozen’s DME Candidate
Surrozen announced on Oct. 2 that the US FDA had signed off on its investigational new drug application, allowing the company to proceed with a clinical trial of SZN-8141, a bifunctional Wnt agonis...
Provider Surveys & Interviews
Grab a seat at the table and join the thousands of ophthalmologists and optometrists from over 60 countries who are helping shape the next generation of diagnostics, pharmaceuticals, devices, and equipment by sharing your opinion and experience. Make your voice heard!
Choose Your Own Adventure
Participation options include weekly polls, special sponsored surveys, syndicated quarterly surveys, focus groups, and interviews, each with varying levels of honoraria.
Safe, Secure & On Any Device
We follow all industry standards to ensure confidentiality between participants and clients. Start and stop surveys anytime on our free Market Scope+ App or on desktop, each with a personalized dashboard just for you.
Pre-Qualified Invitations
We individually verify all potential participants before each survey or interview, ensuring that only licensed eye care professionals are invited and they are never kicked out or disqualified.
Better Data = Better Decisions
A team of industry experts and analysts review each data point, so you can be confident in the results and trends provided in our reports.
Download the Market Scope+ app to get started!
Market Scope Methodology
A Multi-Step Approach for Accurate & Timely Data
Proprietary data
- 20+ years of physician survey data
- Disease models
- Cultivated database of physicians, ASCs, and hospitals
- Insight from our team of in-house industry experts
Public data
- Attendance and participation at major, worldwide meetings
- Public health systems and registries
- Clinical study data
- Analysis of company-published financial reports
Join Market Scope Today
Register A Corporate Account
Register A Clinical Account
A clinical account gives you access to survey participation and results, weekly polls, benchmark reports, a searchable news archive, and more on a personalized dashboard.